Alkermes Completes Acquisition of Avadel Pharmaceuticals; Shares to Delist
Summary
Alkermes plc has completed its acquisition of Avadel Pharmaceuticals, resulting in Avadel becoming a wholly-owned subsidiary and its shares being delisted from Nasdaq.
Key Events
-
Acquisition Completed
Alkermes plc has completed the acquisition of Avadel Pharmaceuticals plc, making Avadel a wholly-owned subsidiary, following the Irish High Court's sanction on February 10, 2026.
-
Shareholder Consideration
Avadel shareholders will receive $21.00 in cash per share and one non-transferable contingent value right (CVR) with a potential additional cash payment of $1.50 per share upon milestone achievement.
-
Delisting from Nasdaq
Avadel has requested Nasdaq to halt trading of its shares and will proceed with delisting from the Nasdaq Global Market and deregistration under the Securities Exchange Act of 1934.
-
Executive and Board Changes
All executive officers, including the CEO, CFO, COO, and General Counsel, along with all board members, ceased their roles at Avadel as a result of the acquisition.
Analysis
This filing marks the definitive completion of the acquisition of Avadel Pharmaceuticals by Alkermes plc, a major corporate event that fundamentally alters Avadel's status. As a result, Avadel ceases to be an independent public company, becoming a wholly-owned subsidiary of Alkermes. Shareholders will receive a cash payout and a contingent value right, and the company's shares will be delisted from Nasdaq. This is the final step in a process that began with the transaction agreement and subsequent shareholder and court approvals, providing a definitive resolution for investors.
At the time of this filing, AVDL was trading at $21.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $6.38 to $23.57. This filing was assessed with neutral market sentiment and an importance score of 10 out of 10.